Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

‘Sister Study ’ Looks at Genetic, Environmental Breast Cancer Links

December 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

RESEARCH TRIANGLE PARK, North Carolina-Researchers have begun the first phase of a long-term, prospective epidemiological study designed to determine the role of genetic, environmental, and lifestyle factors in increasing the risk of breast cancer and several other diseases. The Sister Study is the first long-term follow-up study specifically designed to look at hereditary and environmental risk factors for the disease. It seeks to enroll 50,000 cancer-free women in the United States between the ages of 35 and 74 who have a sister diagnosed with breast cancer.

RESEARCH TRIANGLE PARK, North Carolina—Researchers have begun the first phase of a long-term, prospective epidemiological study designed to determine the role of genetic, environmental, and lifestyle factors in increasing the risk of breast cancer and several other diseases. The Sister Study is the first long-term follow-up study specifically designed to look at hereditary and environmental risk factors for the disease. It seeks to enroll 50,000 cancer-free women in the United States between the ages of 35 and 74 who have a sister diagnosed with breast cancer.

"Our overall goal is to create a framework from which we, and others who might collaborate with us, can ask questions about the role of the external environment, which has not been studied very well in breast cancer risk," said co-principal investigator Dale Sandler, PhD.

Dr. Sandler is the acting chief of the Epidemiology Branch at the National Institute of Environmental Health Sciences (NIEHS). The institute is funding the project, which is expected to cost about $7 million a year. Clarice Weinberg, PhD, chief of NIEHS’s Biostatistics Branch, is the other co-principal investigator.

"The Sister Study is unique among cohort studies in the emphasis we have put on external environmental exposures," Dr. Sandler said. "The current cohort studies— the Nurses’ Health Study and others— really focus on lifestyle. In the Sister Study, we are trying to address this other piece of the puzzle, the environment."

Researchers began recruiting for the study in Tampa, Florida, in September and have expanded their efforts to Phoenix, Arizona; St. Louis, Missouri; and Providence, Rhode Island, all chosen for the initial phase of the study because of their size and geographic, ethnic, and socioeconomic diversity.

The target enrollment for the four cities is 2,000 women over 6 to 9 months. Using the experience they gain from enrolling women from the initial four cities, the research team will refine its recruiting strategies and launch a national enrollment effort in the summer of 2003.

Dr. Sandler and her colleagues have enlisted breast cancer advocates and other groups to aid in enrollment. The initial recruitment effort took place during the Tampa Bay area Race for the Cure. "We have built a list of volunteers who are connected with different organizations throughout the United States, who have agreed to help us recruit women," Dr. Sandler said.

The sister of a woman who develops breast cancer has up to double the risk of getting the disease herself. "This is due to a combination of their shared genetics and probably their shared environmental and lifestyle exposures," Dr. Sandler said. "They share their early lives, and they take many of their habits and diet with them into their separate adult lives."

Followed for at Least 10 Years

Participants in the Sister Study will be followed for at least 10 years in an effort to determine whether the increased risk for breast cancer lies in such things as shared genes, a common diet, early menstruation, a household or environmental chemical, and/or a gene-environment interaction. Researchers will also look for factors that might prevent breast cancer. During each year of the study, about 300 participants are expected to be diagnosed with the disease.

Although its primary focus is on breast cancer, the Sister Study will also investigate risk factors for ovarian and endometrial cancer, as well as cardiovascular disease, osteoporosis, autoimmune diseases, and thyroid diseases, Dr. Sandler said.

At the study’s outset, researchers will collect biological and environmental samples from the women—including blood, urine, toenail clippings, and dust from their homes—to measure certain chemicals, hormones, and environmental substances. The samples will be stored for later analyses. "As women develop breast cancer, we will analyze the samples and compare the results with those from the women who didn’t develop breast cancer," Dr. Sandler said.

Each woman will also answer a detailed questionnaire about her family history, lifestyle, diet, occupational history, residence, medical and reproductive history, and environmental exposures. Thereafter, each participant will answer a shorter questionnaire annually.

The Sister Study has few exclusion criteria. Women are eligible for the study whether or not their sister diagnosed with breast cancer is living or dead, or whether she is a full sister or half sister.

Beginning in December, the study will also enroll a limited number of women who have been diagnosed with breast cancer for the first time within the past 4 months and have an eligible sister without breast cancer.

The researchers expect the Sister Study to return statistically significant, long-term data. "We are studying a group of women who want to be studied," Dr. Sandler said. "These women are concerned about breast cancer because they have it in their family; they want to do something. We think that we are going to be able to do this very well, whereas other cohorts may have more difficulty in terms of compliance."

Additional information is available online at http://www.sisterstudy.org or by calling 1-877-474-7837. 

Articles in this issue

Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma
Stereotactic Radiosurgery Benefits Brain Met Patients
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Report
Tailored Messages Motivate Women to Get Mammograms
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Preoperative Capecitabine/RT Downstages Rectal Cancer
Intraoperative Lymphatic Mapping Enhances Cancer Staging
Rituximab Ups Survival in Aggressive and Indolent NHL
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial
Lower Breast Cancer Survival in Hispanics: New Mexico Study
Concurrent Chemo/RT More Likely to Save Larynx
Rituximab Improves Paclitaxel/ Topotecan Salvage Efficacy in NHL
CT Growth Assessment Reliably Diagnoses Solid Lung Nodules
Fludarabine Combos Showing Efficacy in Lymphomas
EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Advertisement

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


Strategizing ADC Use to Enhance Breast Cancer Outcomes

Strategizing ADC Use to Enhance Breast Cancer Outcomes

Ariana Pelosci
July 17th 2025
Article

Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.

Related Content
Advertisement

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


Strategizing ADC Use to Enhance Breast Cancer Outcomes

Strategizing ADC Use to Enhance Breast Cancer Outcomes

Ariana Pelosci
July 17th 2025
Article

Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.